000403.SZ
Pacific Shuanglin Bio-pharmacy Co., Ltd.
SZSE · Healthcare · C 制造业 · CN
CNY 9.47
−0.84%Oct 8, 2026, 09:57 UTC
Pulin Bio reported that it had repurchased 12.8535 million shares, or 1.35% of its total share capital, for a total of RMB 138 million as of September 30, 2026.
Source:Aug 23, 2026, 13:25 UTC
Pailin Biologics reported its 2026 first-half results on August 23, with net profit attributable to shareholders down 64.25% year-on-year to 84.301 million yuan and revenue down 15.88% to 830 million yuan.
Aug 23, 2026, 13:25 UTC
Pailin Biologics proposed a cash dividend of 1.5 yuan per 10 shares (tax included) for the first half of 2026.